» Articles » PMID: 31007035

HIV Research for Prevention 2018: From Research to Impact Conference Summary and Highlights

Abstract

The HIV Research for Prevention (HIVR4P) conference is dedicated to advancing HIV prevention research, responding to a growing consensus that effective and durable prevention will require a combination of approaches as well as unprecedented collaboration among scientists, practitioners, and community workers from different fields and geographic areas. The conference theme in 2018, "From Research to Impact," acknowledged an increasing focus on translation of promising research findings into practical, accessible, and affordable HIV prevention options for those who need them worldwide. HIVR4P 2018 was held in Madrid, Spain, on 21-25 October, with >1,400 participants from 52 countries around the globe, representing all aspects of HIV prevention research and implementation. The program included 137 oral and 610 poster presentations. This article presents a brief summary of highlights from the conference. More detailed information, complete abstracts as well as webcasts and daily Rapporteur summaries may be found on the conference website.

Citing Articles

Exploring HIV risk perception mechanisms among youth in a test-and-treat trial in Kenya and Uganda.

Owino L, Johnson-Peretz J, Lee J, Getahun M, Coppock-Pector D, Maeri I PLOS Glob Public Health. 2024; 4(5):e0002922.

PMID: 38696376 PMC: 11065277. DOI: 10.1371/journal.pgph.0002922.


TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice.

Godot V, Tcherakian C, Gil L, Cervera-Marzal I, Li G, Cheng L PLoS Pathog. 2020; 16(11):e1009025.

PMID: 33253297 PMC: 7728200. DOI: 10.1371/journal.ppat.1009025.


Advances in Long-Acting Agents for the Treatment of HIV Infection.

Rana A, Castillo-Mancilla J, Tashima K, Landovitz R Drugs. 2020; 80(6):535-545.

PMID: 32180205 PMC: 7206978. DOI: 10.1007/s40265-020-01284-1.


Predictors of availability of long-acting medication for opioid use disorder.

Shover C, Humphreys K Drug Alcohol Depend. 2019; 204:107586.

PMID: 31593871 PMC: 6910228. DOI: 10.1016/j.drugalcdep.2019.107586.

References
1.
Kim J, Excler J, Michael N . Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med. 2014; 66:423-37. DOI: 10.1146/annurev-med-052912-123749. View

2.
Corey L, B Gilbert P, Tomaras G, Haynes B, Pantaleo G, Fauci A . Immune correlates of vaccine protection against HIV-1 acquisition. Sci Transl Med. 2015; 7(310):310rv7. PMC: 4751141. DOI: 10.1126/scitranslmed.aac7732. View

3.
. Abstracts of the HIV Research for Prevention Meeting, HIVR4P, 17-20 October, 2016, Chicago, USA. AIDS Res Hum Retroviruses. 2017; 32(S1):1-409. DOI: 10.1089/aid.2016.5000.abstracts. View